BidaskClub Upgrades Xenon Pharmaceuticals (XENE) to Strong-Buy

Share on StockTwits

BidaskClub upgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, August 11th. Jefferies Financial Group reissued a buy rating and set a $16.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, August 10th. Stifel Nicolaus raised their target price on shares of Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a buy rating in a research note on Wednesday, August 8th. Finally, ValuEngine raised shares of Xenon Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, June 5th. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $12.58.

Xenon Pharmaceuticals stock opened at $13.45 on Wednesday. The company has a current ratio of 20.83, a quick ratio of 20.83 and a debt-to-equity ratio of 0.41. Xenon Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $13.80.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 95.43%. sell-side analysts forecast that Xenon Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Kovack Advisors Inc. acquired a new position in Xenon Pharmaceuticals during the 2nd quarter valued at about $113,000. OppenheimerFunds Inc. boosted its position in shares of Xenon Pharmaceuticals by 104.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 22,481 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 11,476 shares in the last quarter. Spark Investment Management LLC boosted its position in shares of Xenon Pharmaceuticals by 105.5% during the 2nd quarter. Spark Investment Management LLC now owns 26,100 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 13,400 shares in the last quarter. Elmwood Wealth Management Inc. boosted its position in shares of Xenon Pharmaceuticals by 100.0% during the 2nd quarter. Elmwood Wealth Management Inc. now owns 37,458 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 18,729 shares in the last quarter. Finally, JBF Capital Inc. bought a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at about $368,000. 47.26% of the stock is currently owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

Featured Story: Marijuana Stocks

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply